Pramlintide (Pramlintide (Symlin))
An FDA-approved synthetic analog of the hormone amylin, used alongside insulin in diabetes. It slows gastric emptying and promotes satiety, and is of interest in biohacker circles for appetite control and glucose management.
How it works
Mimics amylin by activating amylin receptors, which slows gastric emptying, suppresses inappropriate glucagon secretion after meals, and increases satiety - complementing insulin's effects.
Key facts
- Molecular weight: 3949.4 Da
- Half-life: ~48 minutes
- Bioavailability: Subcutaneous injection
- Storage: Refrigerate (2-8°C); in-use pens may be kept per label for a limited time.
Dosing overview
- Typical dose: 15-120 mcg before meals
- Frequency: Before major meals
- Duration: Ongoing
- Route: Subcutaneous injection
Protocol notes
- Prescribed dosing starts low (e.g. 15-30 mcg) before meals and titrates up to limit nausea.
- Injected separately from insulin (not mixed) before major meals.
- Blood glucose is monitored, especially when used with insulin.
Reported benefits
- Appetite suppression and satiety
- Slows gastric emptying
- Improves post-meal glucose control
- Modest weight loss
Possible side effects
- Nausea
- Hypoglycemia (with insulin)
- Reduced appetite
- Injection site reactions
Research
- Pramlintide and weight in insulin-treated patients (2016): Improved glycemic control and produced modest weight loss versus insulin alone.
Compare Pramlintide
Research and educational reference only. Not medical advice.